LEADER 01085nam a2200253|i 4500 001 991003789709707536 005 20021223130716.0 008 021003s1998 it u u enguu 035 $ab11864370-39ule_inst 035 $aLE02988501$9ExL 040 $aISUFI - Sett. Diritti e Politiche Euromediterranee$bita 082 0 $a344.046 100 1 $aDeketelaere, Kurt$0532181 245 10$aNew instruments for environmental policy in the EU :$bnew environmental poliy instruments in Belgium /$cKurt Deketelaere 260 0 $aBadia Fiesolana, San Domenico (FI) :$bEuropean university institute,$cc1998 300 $a21 p. ;$c21 cm 490 0 $aEUI working paper Robert Schuman Centre ;$v98/16 650 4$aAmbiente - nuovi strumenti - Belgio 907 $a.b11864370$b28-04-17$c23-12-02 912 $a991003789709707536 945 $aLE029 344.046 DEK01.01$g1$iLE029-4280$lle029$o-$pE0.00$q-$rn$so $t0$u0$v0$w0$x0$y.i12116890$z23-12-02 996 $aNew instruments for environmental policy in the EU$9901467 997 $aUNISALENTO 998 $ale029$b01-01-02$cm$da $e-$feng$git $h0$i1 LEADER 07289nam 2200565 450 001 9910164945803321 005 20230828204136.0 010 $a0-85711-113-2 035 $a(CKB)3450000000001769 035 $a(MH)010521173-7 035 $a(SSID)ssj0000371017 035 $a(PQKBManifestationID)12125388 035 $a(PQKBTitleCode)TC0000371017 035 $a(PQKBWorkID)10375886 035 $a(PQKB)10805612 035 $a(MiAaPQ)EBC5163842 035 $a(MiAaPQ)EBC5292371 035 $a(Au-PeEL)EBL5292371 035 $a(CaONFJC)MIL993871 035 $a(OCoLC)1028942673 035 $a(EXLCZ)993450000000001769 100 $a20181020d2006 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAdverse drug reactions /$fedited by Anne Lee 205 $a2nd ed. 210 1$aLondon ;$aChicago :$cPharmaceutical Press,$d2006. 215 $a1 online resource (xxi, 474 p. ) 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a0-85369-601-2 320 $aIncludes bibliographical references and index. 327 $aCover -- Prelims -- Contents -- Preface -- Acknowledgements -- About the editor -- Contributors -- Chapter 1 - Introduction -- Epidemiology -- Classification and mechanisms -- Susceptibility -- Detection and diagnosis -- Healthcare professionals and adverse drug reactions -- References -- Further reading -- Chapter 2 - Side effects and patients -- Introduction -- Desire for information about side effects -- General perceptions -- Side effects and compliance -- Mandatory patient information leaflets -- Format of side-effect data for patients -- Key effects to consider when presenting side-effect data -- Patient reporting of ADRs -- The way forward -- References -- Further reading -- Chapter 3 - Pharmacogenetics and adverse drug reactions -- Introduction -- Adverse drug reactions -- Drug action -- Genetics revisited -- Genetic polymorphism and drug transporters -- Genetically determined pharmacodynamic variations -- Human leukocyte antigens and adverse drug reactions -- Utility of pharmacogenetics in the clinical setting -- References -- Further reading -- Glossary -- Chapter 4 - Adverse drug reactions in pregnancy -- Introduction -- Prescribing in pregnancy -- Drugs used to treat selected cardiovascular system disorders -- Drugs used to treat epilepsy -- Mental health disorders -- Drugs used in endocrine disorders -- Drugs used to treat infections -- Miscellaneous agents -- Summary -- References -- Further reading -- Glossary -- Chapter 5 - Drug-induced skin reactions -- Introduction -- Classification and mechanism -- Diagnosis -- Management points -- Exanthematous (erythematous) reactions -- Fixed drug eruption -- Urticaria and angio-oedema -- Acne -- Psoriasis and psoriasiform eruptions -- Purpura -- Vasculitis -- Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis -- Blistering drug eruptions -- Photosensitivity. 327 $aLichenoid drug eruptions -- Pigmentary disorders -- Alopecia -- Hair gain -- Nail disorders -- References -- Further reading -- Chapter 6 - Gastrointestinal disorders -- Introduction -- The mouth -- The oesophagus -- Nausea and vomiting -- Stomach and duodenum -- Small intestine -- Colon -- Constipation -- Pancreatitis -- References -- Further reading -- Chapter 7 - Hepatic disorders -- Introduction -- Classification and mechanisms -- Signs and symptoms of liver disorders -- Risk factors -- Diagnosis of drug-induced liver damage -- Types of drug-induced liver disease -- Management of patients with drug-induced hepatic disease -- Prevention of drug-induced hepatic damage -- References -- Further reading -- Chapter 8 - Renal disorders -- Introduction -- Risk factors -- Diagnosis of drug-induced renal dysfunction -- Acute renal failure -- Chronic renal failure -- Nephrogenic diabetes insipidus -- Haemolytic uraemic syndrome -- Osmotic nephrosis -- Conclusion -- References -- Further reading -- Chapter 9 - Endocrine and metabolic disorders -- Introduction -- Drugs affecting thyroid function -- Medicines that may interfere with thyroid function tests -- Drugs affecting adrenal function -- Aldosterone synthesis -- Drugs affecting gonadotrophin release and gonadal function -- Hyperprolactinaemia -- Syndrome of inappropriate secretion of antidiuretic hormone -- Hyperglycaemia and diabetes -- Hypoglycaemia -- Disorders of fat metabolism -- References -- Further reading -- Chapter 10 - Respiratory disorders -- Introduction -- Nasal congestion -- Airway obstruction -- Parenchymal lung disorders -- Pulmonary oedema -- Pulmonary thromboembolism -- References -- Further reading -- Chapter 11 - Musculoskeletal disorders -- Introduction -- Muscle disorders -- Bone -- Joints -- Connective tissue -- References -- Further reading -- Chapter 12 - Blood disorders. 327 $aIntroduction -- Aplastic anaemia -- Agranulocytosis -- Thrombocytopenia -- Pure red cell aplasia -- Haemolytic anaemia -- Megaloblastic anaemia -- References -- Further reading -- Chapter 13 - Mental health disorders -- Introduction -- Depression -- Psychosis -- Mania -- Behavioural toxicity -- Cognitive impairment -- Psychiatric manifestations of drug withdrawal reactions -- Use of SSRIs and venlafaxine in children and adolescents with major depressive disorder (MDD) -- Serotonin syndrome and neuroleptic malignant syndrome -- Management of drug-induced psychiatric disturbances -- References -- Further reading -- Chapter 14 - Cardiovascular effects -- Introduction -- Disorders of cardiac rhythm -- Disorders of systemic blood pressure -- Congestive heart failure -- Myocardial toxicity -- Pulmonary hypertension -- Stroke and heart attack risk -- References -- Further reading -- Chapter 15 - Neurological disorders -- Introduction -- Headache -- Effects on the neuromuscular junction and myasthenia gravis -- Seizures -- Coma and encephalopathy -- Neuropathies -- Guillain-Barre? syndrome -- Drug-induced movement disorders -- Sudden sleep onset with dopaminergic drugs -- References -- Chapter 16 - Sexual dysfunction and infertility -- Introduction -- Infertility -- Sexual dysfunction -- References -- Further reading -- Index. 330 $aAdverse reactions to medicines continue to present a considerable burden on healthcare, causing considerable morbidity and mortality. As well as knowing about the benefits of medicines, healthcare professionals need to understand the problem of adverse drug reactions and be aware of how they can be prevented and managed. The new edition of this essential and practical guide has been extensively revised and updated. 606 $aDrugs$xSide effects$vHandbooks, manuals, etc 615 0$aDrugs$xSide effects 676 $a615/.7042 702 $aLee$b Anne$f1963- 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910164945803321 996 $aAdverse drug reactions$92872834 997 $aUNINA 999 $aThis Record contains information from the Harvard Library Bibliographic Dataset, which is provided by the Harvard Library under its Bibliographic Dataset Use Terms and includes data made available by, among others the Library of Congress LEADER 01947nam 2200529 450 001 9910708693603321 005 20170821163830.0 010 $a1-60127-163-8 035 $a(CKB)2670000000378428 035 $a(EBL)4471542 035 $a(SSID)ssj0001054959 035 $a(PQKBManifestationID)11689766 035 $a(PQKBTitleCode)TC0001054959 035 $a(PQKBWorkID)11005985 035 $a(PQKB)11140393 035 $a(MiAaPQ)EBC4471542 035 $a(OCoLC)830004933$z(OCoLC)902735364$z(OCoLC)946786886 035 $a(EXLCZ)992670000000378428 100 $a20160422h20132013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aJustifying the means $eAfghan perceptions of electoral processes /$fNoah Coburn, Anna Larson 210 1$aWashington, District of Columbia :$cUnited States Institute of Peace Press,$d2013. 210 4$d©2013 215 $a1 online resource (16 p.) 225 1 $aSpecial Report (United States Institute of Peace) ;$v326 300 $aDescription based upon print version of record. 320 $aIncludes bibliographical references (page 16). 327 $aContents ; Summary; Introduction; The Impact of Previous Elections; Two Types of Electoral Fraud; Perceptions of "Free and Fair"; The Fear of Political Uncertainty; A Concern for Outcomes Over Processes; Elections and Transition in 2014; Notes 410 0$aSpecial report (United States Institute of Peace) ;$v326. 606 $aElections$zAfghanistan 607 $aAfghanistan$xPolitics and government$y2001- 615 0$aElections 676 $a324.9581 700 $aCoburn$b Noah$01143375 702 $aLarson$b Anna 712 02$aUnited States Institute of Peace, 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910708693603321 996 $aJustifying the means$93298546 997 $aUNINA LEADER 01161nam0 22002771i 450 001 UON00248406 005 20231205103620.711 100 $a20040121d1980 |0itac50 ba 101 $aita 102 $aIT 105 $a|||| ||||| 200 1 $aˆLa ‰politica estera etiopica e le questioni Eritrea e Somala (1941-1960)$fPier Giacomo Magri 205 $aMilano : Giuffré$b1980 210 $a259 p.$a26 cm 215 $aNel front.: Università degli Studi di Urbino, Facoltà di Giurisprudenza 606 $aETIOPIA$xRelazioni estere$xEritrea$3UONC019605$2FI 620 $aIT$dMilano$3UONL000005 676 $a327.630635$cETIOPIA - Relazioni con l'Eritrea$v21 700 1$aMAGRI$bPier Giacomo$3UONV146445$0228901 712 $aGiuffrè$3UONV257275$4650 801 $aIT$bSOL$c20240220$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00248406 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI ET IV E a 149 $eSI AA 26130 7 149 996 $aPolitica estera etiopica e le questioni eritrea e somala (1941-1960$9582038 997 $aUNIOR